Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 180

1.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

Margel D, Nandy I, Wilson TH, Castro R, Fleshner N.

J Urol. 2013 Dec;190(6):2039-45. doi: 10.1016/j.juro.2013.06.051. Epub 2013 Jun 29.

PMID:
23820059
[PubMed - indexed for MEDLINE]
2.

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R; REDEEM Study Group.

Contemp Clin Trials. 2007 Nov;28(6):763-9. Epub 2007 May 29.

PMID:
17573244
[PubMed - indexed for MEDLINE]
3.

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS.

Lancet. 2012 Mar 24;379(9821):1103-11. doi: 10.1016/S0140-6736(11)61619-X. Epub 2012 Jan 24.

PMID:
22277570
[PubMed - indexed for MEDLINE]
4.

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.

BJU Int. 2012 Sep;110(5):651-7. doi: 10.1111/j.1464-410X.2011.10875.x. Epub 2012 Jan 30.

PMID:
22289613
[PubMed - indexed for MEDLINE]
5.

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

PMID:
21699645
[PubMed - indexed for MEDLINE]
6.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025. Epub 2012 May 18.

PMID:
22658758
[PubMed - indexed for MEDLINE]
7.

Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.

Shelton PQ, Ivanowicz AN, Wakeman CM, Rydberg MG, Norton J, Riggs SB, Teigland CM.

Urology. 2013 May;81(5):979-84. doi: 10.1016/j.urology.2012.10.089. Epub 2013 Mar 20.

PMID:
23523297
[PubMed - indexed for MEDLINE]
8.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R.

Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.

PMID:
23176897
[PubMed - indexed for MEDLINE]
9.

Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

Reese AC, Landis P, Han M, Epstein JI, Carter HB.

J Urol. 2013 Dec;190(6):2033-8. doi: 10.1016/j.juro.2013.05.015. Epub 2013 May 13.

PMID:
23680308
[PubMed - indexed for MEDLINE]
10.

A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B.

J Urol. 2013 Jan;189(1 Suppl):S19-25; discussion S25. doi: 10.1016/j.juro.2012.11.023.

PMID:
23234624
[PubMed - indexed for MEDLINE]
11.

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.

Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP.

BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18.

PMID:
21332630
[PubMed - indexed for MEDLINE]
12.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
[PubMed - indexed for MEDLINE]
13.

Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?

Coen JJ, Feldman AS, Smith MR, Zietman AL.

BJU Int. 2011 May;107(10):1582-6. doi: 10.1111/j.1464-410X.2010.09652.x. Epub 2010 Sep 22.

PMID:
20860650
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

PMID:
20357281
[PubMed - indexed for MEDLINE]
Free Article
15.

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.

Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB.

J Urol. 2013 Oct;190(4):1218-22. doi: 10.1016/j.juro.2013.04.071. Epub 2013 Apr 30.

PMID:
23643603
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J.

Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033.

PMID:
21820580
[PubMed - indexed for MEDLINE]
17.

Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.

Iremashvili V, Manoharan M, Rosenberg DL, Soloway MS.

BJU Int. 2013 Apr;111(4):574-9. doi: 10.1111/j.1464-410X.2012.11127.x. Epub 2012 May 4.

PMID:
22564446
[PubMed - indexed for MEDLINE]
18.
19.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

PMID:
23126653
[PubMed - indexed for MEDLINE]
Free Article
20.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041. Epub 2010 May 15.

PMID:
20478589
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk